Population
Mouse models including conventional cGKI-null mutants (cGKI), gene-targeted cGKIα/β rescue mice, platelet…
Design
Preclinical
Authors
Loading...
IL-6 blockade normalizes platelets in cGKI-deficient mice; leaves open relevance to human thrombosis risk and requires clinical validation.
Dysfunction of cGMP/cGKI signaling in nonhematopoietic cells leads to elevated interleukin-6 production and subsequent thrombocytosis, revealing a mechanism potentially associated with thrombosis.
Zhang et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: